Drug Trial Radar · NCT02603809
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Nov 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,659
Actual
Start
Dec 14, 2015
Primary completion
Feb 28, 2017
Study completion Apr 7, 2017
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension. Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.
Conditions
- Essential Hypertension
Interventions
Aprocitentan 5 mgDrug
One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
Aprocitentan 10 mgDrug
Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.
Aprocitentan 25 mgDrug
One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
Aprocitentan 50 mgDrug
One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
Lisinopril 20 mgDrug
One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan
PlaceboDrug
One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at TroughTime frame: Baseline (Day 1) and end of double-blind treatment (Day 56)
Locations
90 sites in 4 countries. Site status is shown where the registry gives one.
Appalachian Cardiovascular Associates
Fort Payne, Alabama
Radiant Research Inc
Chandler, Arizona
Warner Family Practice / Radiant Research Inc
Chandler, Arizona
Phoenix Medical Research Institute LLC
Peoria, Arizona
Advanced Arizona Clinical Research
Tucson, Arizona
Noble Clinical Research LLC
Tucson, Arizona
Desert Sun Clinical Research LLc
Tucson, Arizona
Advanced Research Center Inc
Anaheim, California
Med Center
Carmichael, California
John Muir Physician Network Clinical Research Center
Concord, California
Clinical Trials Research
Lincoln, California
Long Beach Center for Clinical Research
Long Beach, California
Entertainment Medical Group Inc
Los Angeles, California
Artemis institute for Clinical Research
San Diego, California
Memorial Research Medical Clinic / Orange County Research Center
Tustin, California
Empire Clinical Research
Upland, California
Clinical Research Consulting LLC
Milford, Connecticut
Chase Medical Research LLC
Waterbury, Connecticut
Alfieri Cardiology
Wilmington, Delaware
ACRC - Cardiology
Atlantis, Florida
Innovative Research of West Florida INC
Clearwater, Florida
Avail Clinical Research LLC
DeLand, Florida
Alan Graff, MD, PA
Fort Lauderdale, Florida
Gulfcoast Clinical Research Center
Fort Myers, Florida
AGA Clinical Trials
Hialeah, Florida
Canvas Clinical Research, LLC
Lake Worth, Florida
LCC Medical Research Institute
Miami, Florida
Allied Biomedical Research Institute, INC
Miami, Florida
Southeast Regional Research Group
Savannah, Georgia
Community Clin Res CTR
Anderson, Indiana
Midwest Institute for Clinical Research
Indianapolis, Indiana
Heartland Research Associated LLC
Newton, Kansas
Heartland Research Associates LLC
Wichita, Kansas
Heartland Research Associates LLC
Wichita, Kansas
Avant Research Associates, LLC
Crowley, Louisiana
Best Clinical Trials LLC
New Orleans, Louisiana
New Orleans Center for Clinical Research - Nola
New Orleans, Louisiana
Clinsite LLC
Ann Arbor, Michigan
Primecare Research Associates, LLC
Florissant, Missouri
Clinical Research Advantage, Inc. / Diagnostic Center Of Medicine - Durango
Las Vegas, Nevada
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.